Sec Form 3 Filing - Paravasthu Mukund @ NovoCure Ltd - 2024-10-01

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Paravasthu Mukund 2. Issuer Name and Ticker or Trading Symbol NovoCure Ltd [ NVCR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Operating Officer (Last) (First) (Middle) C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115 3. Date of Earliest Transaction (MM/DD/YY) 10/01/2024 (Street) WAYNE, PA19087 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 3,663 D Restricted Share Units 154 ( 1 ) D Restricted Share Units 826 ( 2 ) D Restricted Share Units 1,989 ( 3 ) D Restricted Share Units 1,138 ( 4 ) D Restricted Share Units 2,381 ( 5 ) D Restricted Share Units 18,463 ( 6 ) D Restricted Share Units 15,337 ( 7 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (Right to buy) $ 153.09 ( 8 ) 03/01/2031 Ordinary Shares 3,848 D Stock Options (Right to buy) $ 153.09 ( 9 ) 03/01/2031 Ordinary Shares 653 D Stock Options (Right to buy) $ 107.73 ( 10 ) 11/01/2031 Ordinary Shares 831 D Stock Options (Right to buy) $ 83.77 ( 11 ) 05/02/2032 Ordinary Shares 10,109 D Stock Options (Right to buy) $ 83.77 ( 12 ) 05/02/2032 Ordinary Shares 148 D Stock Options (Right to buy) $ 80.59 ( 13 ) 02/29/2032 Ordinary Shares 3,260 D Stock Options (Right to buy) $ 80.59 ( 14 ) 02/29/2032 Ordinary Shares 1,086 D Stock Options (Right to buy) $ 76.97 ( 15 ) 02/27/2033 Ordinary Shares 4,644 D Stock Options (Right to buy) $ 76.97 ( 16 ) 02/27/2033 Ordinary Shares 1,299 D Stock Options (Right to buy) $ 73.2 ( 17 ) 10/31/2032 Ordinary Shares 2,902 D Stock Options (Right to buy) $ 64.15 ( 18 ) 05/04/2030 Ordinary Shares 4,674 D Stock Options (Right to buy) $ 64.15 ( 18 ) 05/04/2030 Ordinary Shares 5,421 D Stock Options (Right to buy) $ 16.3 ( 19 ) 02/26/2034 Ordinary Shares 23,251 D Stock Options (Right to buy) $ 16.3 ( 20 ) 02/26/2034 Ordinary Shares 201 D Stock Options (Right to buy) $ 13.54 ( 21 ) 01/10/2034 Ordinary Shares 7,146 D Stock Options (Right to buy) $ 13.54 ( 22 ) 01/10/2034 Ordinary Shares 21,426 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Paravasthu Mukund C/O NOVOCURE INC. 1550 LIBERTY RIDGE DRIVE, SUITE 115 WAYNE, PA19087 Chief Operating Officer Signatures Steven Robbins, as attorney in fact for Paravasthu, Mukund 10/09/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents restricted share units that are scheduled to vest on November 2, 2024, subject to the reporting person's continued employment through such date. ( 10 )Options to buy 831 ordinary shares, 416 shares of which are currently exercisable and the remainder will vest in equal installments on each of November 2, 2024 and 2025, subject to the reporting person's continued employment through such dates. ( 11 )Options to buy 10,109 ordinary shares, 5,129 shares of which are currently exercisable and the remainder will vest in equal installments on each of May 3, 2025 and 2026, subject to the reporting person's continued employment through such dates. ( 12 )These stock options will vest on May 3, 2026, subject to the reporting person's continued employment through such date. ( 13 )Options to buy 3,260 ordinary shares, 2,174 shares of which are currently exercisable and the remainder will vest on March 1, 2025, subject to the reporting person's continued employment through such date. ( 14 )Options to buy 1,086 ordinary shares will vest on March 1, 2026, subject to the reporting person's continued employment through such date. ( 15 )Options to buy 4,644 ordinary shares, 1,486 shares of which are currently exercisable and the remainder will vest in equal installments on each of February 28, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. ( 16 )These stock options will vest on February 28, 2027, subject to the reporting person's continued employment through such date. ( 17 )Options to buy 2,902 ordinary shares, 726 shares of which are currently exercisable and the remainder will vest in equal installments on each of November 1, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. ( 18 )Currently exercisable. ( 19 )Options to buy 23,251 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. ( 2 )Represents restricted share units that are scheduled to vest on March 1, 2025, subject to the reporting person's continued employment through such date. ( 20 )These stock options will vest on February 27, 2028, subject to the reporting person's continued employment through such date. ( 21 )Options to buy 7,146 ordinary shares, 2 shares will vest on January 11, 2025, 1 share will vest on January 11, 2027 and the remaining shares will vest on January 11, 2028, subject to the reporting person's continued employment through such dates. ( 22 )Options to buy 21,426 ordinary shares will vest in equal installments on each of January 11, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. ( 3 )Represents restricted share units that are scheduled to vest on May 3, 2025, subject to the reporting person's continued employment through such date. ( 4 )Represents restricted share units that are scheduled to vest in equal installments on November 1, 2024 and 2025, subject to the reporting person's continued employment through such dates. ( 5 )Represents restricted share units that are scheduled to vest in equal installments on February 28, 2025 and 2026, subject to the reporting person's c ontinued employment through such dates. ( 6 )Represents restricted share units that are scheduled to vest in equal installments on January 11, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. ( 7 )Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. ( 8 )Options to buy 3,848 ordinary shares, 3,376 shares of which are currently exercisable and the remainder will vest on March 2, 2025, subject to the reporting person's continued employment through such date. ( 9 )These stock options will vest on March 2, 2025, subject to the reporting person's continued employment through such date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.